News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
80 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39673)
2015 (44433)
2016 (38330)
2017 (37190)
2018 (39124)
2019 (51338)
2020 (57666)
2021 (58724)
2022 (53929)
2023 (42568)
2024 (38485)
2025 (21142)
Month
January (2883)
February (2030)
March (1769)
April (2200)
May (2664)
June (3162)
July (3087)
August (3801)
September (4260)
October (5136)
November (4629)
December (3503)
Day
1 (335)
2 (311)
3 (237)
4 (70)
6 (2)
7 (48)
8 (54)
9 (56)
10 (84)
11 (40)
13 (1)
14 (80)
15 (90)
16 (78)
17 (59)
18 (31)
20 (1)
21 (91)
22 (78)
23 (75)
24 (68)
25 (25)
26 (1)
28 (4)
29 (222)
30 (262)
31 (261)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Month
January
February
March
April
May
June
July
August
September
October
November
December
Day
1
2
3
4
6
7
8
9
10
11
13
14
15
16
17
18
20
21
22
23
24
25
26
28
29
30
31
Business
Beam Therapeutics Founded by Gene Editing Pioneers to Create Precision Genetic Medicines with Base Editing
Beam Therapeutics announced today that it is launching to develop precision genetic medicines
May 14, 2018
·
6 min read
FDA
BMG Pharma: GelX® Approved in Europe for Prevention of Oral Mucositis in Cancer Patients
BMG Pharma S.r.l., an innovative specialty pharmaceutical company, is pleased to announce the European regulatory approval for its GelX product to be used for the prevention of oral mucositis.
May 14, 2018
·
2 min read
Business
TP Therapeutics Appoints Athena Countouriotis, M.D., as EVP and Chief Medical Officer
TP Therapeutics is a clinical-stage biopharmaceutical company developing oncology therapies with a focus on addressing current drug resistance.
May 14, 2018
·
4 min read
Pharm Country
SCIEX Announces New BioPharmaView Software 3.0 for Streamlining Multiple-Attribute Methods (MAM)
Complete and easy-to-use LC-MS-based solution for biotherapeutics characterization and quality testing
May 14, 2018
·
4 min read
BioMidwest
Ohio Students Seek to Solve Heart Disease, Will Present to State Leaders and Battelle Scientists
Students will present to representatives of the American Heart Association and American Stroke Association, Battelle, the Medical Director of the Ohio Department of Health, and the Ohio Secretary of State.
May 14, 2018
·
3 min read
Drug Development
Arrowhead Doses First Hepatitis B Patients in Multiple Dose Portion of Phase 1/2 Study of ARO-HBV
Arrowhead has also dosed a total of 20 healthy volunteers since the study began on March 27.
May 14, 2018
·
3 min read
BioCapital
Cerner Leads “Big EMR” Market, Epic in “Small EMR” Market, Says Kalorama Information Report
Annual report found market share changed as players dropped out.
May 14, 2018
·
3 min read
Deals
Lilly to Acquire AurKa Pharma
Acquisition Expands Lilly Oncology Pipeline with Early-Phase Asset Being Studied in Multiple Tumor Types
May 14, 2018
·
5 min read
Pharmascience Inc. Launches (Pr)pms-NITROFURANTOIN, First Generic Bioequivalent to MacroBID® Available on the Market, for the Treatment of Urinary Tract Infections
First generic bioequivalent to MacroBID® on the Canadian market
May 14, 2018
·
2 min read
FDA
UCB Announces BRIVIACT® (Brivaracetam) now Approved by FDA to Treat Partial-onset (Focal) Seizures in Pediatric Epilepsy Patients
BRIVIACT CV oral formulations are approved as a monotherapy or adjunctive therapy in patients four years of age and older with partial-onset seizures
May 14, 2018
·
14 min read
Previous
7 of 8
Next